Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients

Arguably, no drug class has more radically and rapidly altered the management of non–small-cell lung cancer (NSCLC) than inhibitors of the interaction between programmed death 1 (PD-1) and its ligand PD-L1. By impeding this negative regulatory signal for T-cell response, PD-1 and PD-L1 inhibitors…

from α1 via xlomafota.13 on Inoreader http://ift.tt/2rFrlKq
via IFTTT